Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    10
    ...
ATC Name B/G Ingredients Dosage Form Price
R03DA05 AMINOPHYLLINE RENAUDIN G Aminophylline - 250mg/10ml 2.5% Injectable solution 739,113 L.L
L02BX03 ABLAX 250 G Abiraterone acetate - 250mg 250mg Tablet L.L
C10AA05 APO-ATORVASTATIN G Atorvastatin (calcium) - 20mg 20mg Tablet 1,088,378 L.L
R03DA05 AMINOPHYLLINE G Aminophylline - 100mg 100mg Tablet, scored 445,388 L.L
L02BX03 ABLAX 500 G Abiraterone acetate - 500mg 500mg Tablet L.L
C10AA05 ASCOVA G Atorvastatin (calcium) - 20mg 20mg Tablet 1,356,641 L.L
J01CA04 AMOXYDIL G Amoxicillin (trihydrate) - 500mg/5ml 500mg/5ml Powder for suspension 218,854 L.L
N02BE51 A.B.C.-COLD G Paracetamol - 500mg, Chlorphenamine maleate - 4mg, Phenylephrine HCl - 5mg Tablet, film coated 534,977 L.L
R03DA05 AMINOPHYLLINE ADULTS G Aminophylline - 350mg 350mg Suppository 244,451 L.L
C09BB04 ANCAVAZ G Amlodipine - 5mg, Perindopril - 5mg Tablet, film coated 491,846 L.L
C10AA05 ATOR MEDIS G Atorvastatin - 20mg 20mg Tablet, film coated 591,291 L.L
J01CA04 AMOXICILLINE ARROW LAB G Amoxicillin (trihydrate) - 1g 1g Tablet, dispersible 940,690 L.L
R03DA05 AMINOPHYLLINE CHILDREN G Aminophylline - 100mg 100mg Suppository 203,496 L.L
S01EA05 ALPHANOVA G Brimonidine tartrate - 0.15% 0.15% Drops solution 599,354 L.L
C10AA05 ATORLIP 20 G Atorvastatin (calcium) - 20mg 20mg Tablet, film coated 1,279,850 L.L
J05AF10 APO-ENTECAVIR G Entecavir - 0.5mg 0.5mg Tablet 28,943,287 L.L
R03DA11 ANSIMAR G Doxofylline - 20mg/ml 20mg/ml Syrup 550,975 L.L
C10AA05 ATORVA TAD G Atorvastatin - 20mg 20mg Tablet, film coated 1,087,169 L.L
J01CA04 AMOXICILLINE INJ. G Amoxicillin (sodium) - 1g 1g Injectable powder for solution 1,173,175 L.L
J05AF10 AVIRAVIR G Entecavir monohydrate - 0.5mg 0.5mg Tablet, film coated 32,224,230 L.L
N06DA02 ALZEPIL G Donepezil HCl - 10mg 10mg Tablet 1,908,256 L.L
R03DA11 ANSIMAR G Doxofylline - 400mg 400mg Tablet 544,256 L.L
C09BB04 ANCAVAZ G Amlodipine - 5mg, Perindopril - 10mg Tablet, film coated 669,234 L.L
C10AA05 ATORVAKEY-20 G Atorvastatin (calcium) - 20mg 20mg Tablet 362,837 L.L
J01CA04 AMOXICILLINE PANPHARMA G Amoxicillin (sodium) - 1g 1g Injectable powder for solution 2,734,719 L.L
N06DA02 ARIPEZIL 10 G Donepezil HCl - 10mg 10mg Tablet, film coated 2,292,595 L.L
C10AA05 ATORVASTATIN PHARMADEX G Atorvastatin - 20mg 20mg Tablet 769,190 L.L
L01XG01 ALVOCADE G Bortezomib - 3.5mg 3.5mg Injectable powder for solution 14,169,600 L.L
L04AX04 APO-LENALIDOMIDE G Lenalidomide - 10mg 10mg Capsule 53,945,075 L.L
M04AA01 ALLOPURINOL BIOGARAN G Allopurinol - 100mg 100mg Tablet 107,507 L.L
    ...
    10
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026